07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Boehringer Ingelheim, Amgen deal

Boehringer granted Amgen worldwide rights to develop and commercialize BI 836909 ( AMG 420), a compound in Phase I testing to treat relapsed and/or refractory multiple myeloma (MM). BI 836909 is a bispecific T...
07:00 , Sep 1, 2016 |  BC Extra  |  Company News

Amgen licenses Boehringer MM candidate

Boehringer Ingelheim GmbH (Ingelheim, Germany) granted Amgen Inc. (NASDAQ:AMGN) global rights to develop and commercialize multiple myeloma candidate BI 836909 (AMG 420). Financial details were not disclosed. BI 836909, a bispecific T cell engager (BiTE)...